FFN Off‑Label Use — Denial Risk

FFN assays used outside covered indications (for example, routine monitoring in asymptomatic individuals with singleton gestation and no risk factors, surveillance of high-risk asymptomatic individuals, use in triplet-or-higher gestations, or to predict imminent delivery at term for induction decisions) may be denied as not meeting coverage criteria.

• Affected codes: FFN-related lab CPT/HCPCS billed without documentation of covered indication and gestational age may be denied.
• Denials likely when FFN is used for routine surveillance, asymptomatic high-risk monitoring, or other non-covered applications listed in the policy.

Conflict with Government Policy

When there is a conflict between this policy and an applicable government policy (e.g., Medicare LCDs/NCDs or state Medicaid coverage), the government policy supersedes this policy. Providers should verify and follow the relevant government coverage guidance for the member at the time of service.

• Check LCDs, NCDs, and state Medicaid rules before ordering if member is Medicare or Medicaid.
• When government policy differs, document adherence to the applicable government requirement to support coverage determinations.

Document Indication and Timing

Document the clinical indication and gestational age (or timing relative to pregnancy) on the medical record and on the claim when ordering prenatal screening tests to support medical necessity and coverage.

• Include reason for test (e.g., symptomatic preterm labor, high-risk exposure, routine first prenatal visit screening) and current gestational weeks.
• For repeat/third‑trimester screening, document risk factors that meet the policy's high‑risk criteria.

Risk and Timing Documentation

Document relevant risk factors and timing to substantiate coverage for rescreening or targeted tests. Risk documentation should reflect the policy definitions of 'increased risk' or 'certain groups' where applicable.

• Examples of risk documentation: age <25, new or multiple sexual partners, prior STI, injection drug use, residence in high‑morbidity area, unknown paternal Rh status.
• For third‑trimester rescreening (HIV, syphilis, chlamydia, gonorrhea), document which high‑risk criterion is met and the gestational week when testing is done.

LDTs and CLIA Documentation

Laboratory‑developed tests (LDTs) used for prenatal screening are regulated as high‑complexity tests under CLIA '88. Providers and labs should ensure appropriate CLIA certification and retain validation documentation to support reimbursement.

• LDTs are considered high‑complexity under CLIA '88; FDA approval/clearance is not required for clinical use but does not substitute for CLIA compliance.
• Lack of appropriate CLIA classification/certification or missing validation documentation may affect reimbursement.

Anti‑D Immune Globulin — Documentation

Anti‑D immune globulin administration is an established prevention strategy for RhD alloimmunization. Document maternal Rh(D) status, antibody screen results, paternal Rh(D) status when known, and timing of anti‑D administrations (postpartum and/or third trimester) to support medical necessity and billing.

• Document indication for anti‑D (e.g., RhD‑negative unsensitized individual, postpartum delivery of RhD‑positive infant, antenatal prophylaxis at 28 weeks).
• Record dose, administration date, and relevant infant Rh status when applicable.

Gestational Diabetes (GDM) Two‑Step Suggestion

The guideline‑recommended two‑step approach for gestational diabetes screening (one‑hour oral glucose challenge followed by the three‑hour OGTT for those who screen positive) at 24–28 weeks is suggested; when following this approach, document screening results and timing to support coverage of subsequent diagnostic testing.

• If the one‑hour screen is positive, document the value and the decision to proceed to the three‑hour OGTT and its timing (24–28 weeks).
• If screening earlier at first prenatal visit for type 2 diabetes due to risk factors, document the risk factors prompting early testing.